ADX-2191 (intravitreal methotrexate 0.8%)

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Proliferative Vitreoretinopathy

Conditions

Proliferative Vitreoretinopathy

Trial Timeline

Nov 15, 2019 → Jun 14, 2022

NCT ID

NCT04136366

About ADX-2191 (intravitreal methotrexate 0.8%)

ADX-2191 (intravitreal methotrexate 0.8%) is a phase 3 stage product being developed by Aldeyra Therapeutics for Proliferative Vitreoretinopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04136366. Target conditions include Proliferative Vitreoretinopathy.

What happened to similar drugs?

3 of 9 similar drugs in Proliferative Vitreoretinopathy were approved

Approved (3) Terminated (2) Active (4)

🔄Brolucizumab 6 mgNovartisPhase 3

✅LucentisNovartisApproved

✅RanibizumabNovartisApproved

❌Octreotide, 30 mg i.m. LAR formulationNovartisPhase 3

✅Macugen ® (pegaptanib sodium)PfizerApproved

🔄Intravitreal aflibercept injection [IAI] + ShamRegeneron PharmaceuticalsPhase 3

🔄Ruxolitinib + PlaceboIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04136366	Phase 3	Completed	Nov 15, 2019	Jun 14, 2022	Proliferative Vitreoretinopathy

Competing Products

20 competing products in Proliferative Vitreoretinopathy

See all competitors

Product	Company	Stage	Hype Score
LY2784544	Eli Lilly	Phase 1	29
LY2784544	Eli Lilly	Phase 1	29
Navitoclax + Ruxolitinib + Celecoxib	AbbVie	Phase 1	33
Epcoritamab	AbbVie	Phase 1	36
Brolucizumab 6 mg	Novartis	Phase 3	40
CANAKINUMAB (ILARIS®)	Novartis	Phase 1	21
Lucentis	Novartis	Approved	43
Ranibizumab	Novartis	Approved	39
Octreotide, 30 mg i.m. LAR formulation	Novartis	Phase 3	32
Ranibizumab 0.5 mg	Novartis	Phase 2	35
AUY922	Novartis	Phase 2	27
Lucentis	Roche	Pre-clinical	22
Macugen (pegaptanib) + Macugen (Pegaptanib)	Pfizer	Pre-clinical	26
Macugen ® (pegaptanib sodium)	Pfizer	Approved	39
Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine	Swedish Orphan Biovitrum	Phase 2	42
Fedratinib Pill	Bristol Myers Squibb	Phase 2	39
VAC85135 + Ipilimumab	Bristol Myers Squibb	Phase 1	29
Fedratinib Pill	Bristol Myers Squibb	Phase 1	21
Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg	Bristol Myers Squibb	Phase 1	21
Aflibercept	Regeneron Pharmaceuticals	Phase 2	35